MedPath

Propranolol Rescue of Prolonged Labor

Phase 3
Terminated
Conditions
Pregnancy, Prolonged
Interventions
Registration Number
NCT04299438
Lead Sponsor
Lisa Levine
Brief Summary

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in women given IV propranolol versus placebo for treatment of prolonged labor.

Detailed Description

A double-blind placebo controlled randomized trial comparing cesarean delivery rates in 326 women given IV propranolol (2 mg with one possible repeat dose greater than 2 hours later) versus IV placebo for treatment of prolonged labor.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
164
Inclusion Criteria

English-speaking

>= 36 weeks gestation

Singleton pregnancy

Vertex presentation

No contraindication to a vaginal delivery

Meets at least one study criteria for prolonged labor:

  1. cervical dilation <6 cm after ≥8 hours with ruptured membranes and receiving oxytocin OR
  2. cervical dilation >=6 cm and <1 cm dilation change over ≥2 hours with ruptured membranes and receiving oxytocin
Exclusion Criteria

Severe preeclampsia: as patients will be receiving magnesium and possibly labetalol for hypertension control

Receiving other beta blocker

Maternal heart rate < 70 beats per minute, systolic blood pressure <90 mmHg, or diastolic blood pressure <50 mmHg on two sets of vital signs in the 1 hour prior to study drug administration: given that bradycardia and hypotension are possible side effects of propranolol

History of any form of asthma: as this is a contraindication to beta blocker use

Diabetes requiring insulin in labor: given the potential risk of neonatal hypoglycemia in the neonate

Any cardiac condition for which β blockade is contraindicated (cardiogenic shock, sinus bradycardia, and greater than first degree heart block)

Known hypersensitivity to propranolol

Intrauterine fetal demise since different labor protocols are used in these women

Major fetal congenital anomaly since rate of cesarean may be inherently different in these women, unrelated to labor

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
PropranololPropranolol HydrochlorideIV Propranolol - 2mg; one possible repeat dose ≥2 hours later
PlaceboSalineNormal saline placebo- 2 mL; one possible repeat dose ≥2 hours later
Primary Outcome Measures
NameTimeMethod
Mode of DeliveryFrom enrollment into the trial until delivery.

Number of participants with a cesarean delivery

Secondary Outcome Measures
NameTimeMethod
Maternal Morbidityfrom delivery through 4 weeks postpartum

Number of participants with 1 or more of the following: blood transfusion, endometritis, wound infection, venous thromboembolism, hysterectomy, ICU admission, readmission, death

Neonatal Morbidityfrom delivery through hospital discharge, usually 2-4 days

Number of participants with 1 or more of the following: Intensive care nursery admission \>48, blood transfusion, hypoxic-ischemic encephalopathy, intraventricular hemorrhage grade 3 or 4, neonatal head cooling, severe respiratory distress syndrome, necrotizing enterocolitis, sepsis, death

Postpartum Hemorrhagefrom time of delivery through hospital discharge, usually 2-4 days

Amount of blood loss measured in mL

Length of Laborhours from start of labor or induction of labor to time of delivery

Time in hours from start of labor or induction of labor to delivery

Chorioamnionitisfrom start of labor through delivery

Number of participants with chorioamnionitis

Trial Locations

Locations (2)

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Pennsylvania Hospital

🇺🇸

Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath